Navigating compounded semaglutide: what health care providers need to know.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or empirical data.
PubMed 40966636 · doi:10.37765/ajmc.2025.89787
What was done
This narrative review examined the safety, efficacy, regulatory status, and health care system implications of compounded semaglutide products sold in response to nationwide drug shortages and high costs of FDA-approved formulations.
What was found
The abstract reports no quantitative data. Qualitatively, it highlights that while regulated compounding can address shortages, existing compounded semaglutide formulations may lack standard quality controls, leading to potential dosing errors, adverse outcomes, and exposure to fraudulent batches globally.
Why it matters
It alerts clinicians to the regulatory and safety pitfalls surrounding compounded alternatives to branded semaglutide, emphasizing the provider's role in guiding patients away from illicit or substandard sources.
Limits
The paper is a non-systematic narrative review providing expert opinion rather than original empirical research. The abstract does not report specific search methods, quantitative data, adverse event frequencies, or analytical sample sizes.
Cited by
- supports Under US regulatory rules during an official drug shortage, compounding pharmacies are permitted to manufacture compounded versions of medications to meet the shortage.